

Atty. Dkt. No. 041673-2069

**In the Claims:**

✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  
Please cancel Claims 88, 89, 90, 92, 96, 101-110, 112, 114, 117-122 and 137-140 as directed to non-elected subject matter, or as redundant in view of the claim amendments. This cancellation is without prejudice to later presentation of the cancelled claims in a divisional or continuation application.

In accordance with 37 CFR § 1.121, please substitute for original claims 87, 93, 95, 99, 111, 113 and 116 the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Marked Up Version Showing Changes Made."

F1 87. (Amended) A method for expressing a chimeric CD40 ligand in a CD40<sup>+</sup> human cell, wherein the chimeric CD40 ligand includes one or more human domains derived from a human CD40 ligand gene and one or more murine domains derived from a murine CD40 ligand gene, the method comprising introducing a chimeric polynucleotide encoding the chimeric CD40 ligand into the cell.

F2 93. (Amended) The method of claim 87 wherein the murine domain comprises an extracellular CD40 ligand domain.

F3 95. (Amended) The method of claim 93 wherein the extracellular domain consists of Domain IV.

F4 99. (Amended) The method of claim 87 wherein the chimeric polynucleotide consists of the nucleic acid sequence of SEQ ID NO. 3.

F5 111. (Amended) The method of claim 87 wherein the human CD40<sup>+</sup> cell comprises a neoplastic cell.

Atty. Dkt. No. 041673-2069

F6

113. (Amended) The method of claim 111, wherein the neoplastic cell comprises a neoplastic B cell.

F7

116. (Amended) The method of claim 111 wherein the neoplastic cell comprises a neoplastic T cell.

Please amend the following claims as being directed to species of the invention of generic Claim 87:

F8

94. (Amended) The method of claim 87 wherein the murine CD40 ligand domain comprises Domain III of the murine CD40 ligand.

F9

97. (Amended) The method of claim 87 wherein the murine CD40 ligand comprises Domain I of the murine CD40 ligand.

98. (Amended) The method of claim 87 wherein the murine CD40 ligand comprises Domain II of the murine CD40 ligand.

F10

100. (Amended) The method of claim 87 wherein the chimeric polynucleotide consists of the nucleic acid sequence of SEQ ID NO. 20.

Please add the following new claims as being directed to species within the scope of generic claim 87. The subject matter of the following claims was originally a part of Claim 99, but has been divided into separate claims for ease of examination.

F11

141. (New) The method of claim 87 wherein the chimeric polynucleotide consists of the nucleic acid sequence of SEQ ID NO. 4.

142. (New) The method of claim 87 wherein the chimeric polynucleotide consists of the nucleic acid sequence of SEQ ID NO. 5.

143. (New) The method of claim 87 wherein the chimeric polynucleotide consists of the nucleic acid sequence of SEQ ID NO. 6.